T. Rowe Price Associates
MCRB icon

T. Rowe Price Associates’s Seres Therapeutics MCRB Stock Holding History

T. Rowe Price Associates’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,370
Closed -$64K – 3037
2024
Q3 		$64K Sell
3,370
-10,000
-75% -$203K ﹤0.01% 2896
2024
Q2 		$194K Sell
13,370
-1,536
-10% -$25.6K ﹤0.01% 2601
2024
Q1 		$232K Sell
14,906
-3,277
-18% -$70.7K ﹤0.01% 2546
2023
Q4 		$510K Buy
18,183
+1,590
+10% +$41.8K ﹤0.01% 2160
2023
Q3 		$791K Buy
16,593
+872
+6% +$66.5K ﹤0.01% 1899
2023
Q2 		$1.51M Sell
15,721
-13,483
-46% -$1.47M ﹤0.01% 1592
2023
Q1 		$3.31M Buy
29,204
+77
+0.3% +$8.33K ﹤0.01% 1293
2022
Q4 		$3.26M Buy
29,127
+477
+2% +$64K ﹤0.01% 1282
2022
Q3 		$3.68M Buy
28,650
+215
+0.8% +$22K ﹤0.01% 1260
2022
Q2 		$1.95M Buy
28,435
+25
+0.1% +$2.15K ﹤0.01% 1620
2022
Q1 		$4.05M Buy
28,410
+382
+1% +$58.8K ﹤0.01% 1498
2021
Q4 		$4.67M Sell
28,028
-39,998
-59% -$6.36M ﹤0.01% 1503
2021
Q3 		$9.47M Sell
68,026
-1,366
-2% -$267K ﹤0.01% 1424
2021
Q2 		$33.1M Sell
69,392
-1,475
-2% -$622K ﹤0.01% 1174
2021
Q1 		$29.2M Sell
70,867
-23,296
-25% -$10.7M ﹤0.01% 1177
2020
Q4 		$46.1M Buy
94,163
+65,055
+223% +$38.1M ﹤0.01% 987
2020
Q3 		$16.5M Buy
29,108
+27,799
+2,124% +$9.24M ﹤0.01% 1198
2020
Q2 		$125K Sell
1,309
-1,403
-52% -$123K ﹤0.01% 2414
2020
Q1 		$194K Buy
2,712
+15
+0.6% +$1.01K ﹤0.01% 2321
2019
Q4 		$186K Buy
2,697
+75
+3% +$5.56K ﹤0.01% 2413
2019
Q3 		$210K Buy
2,622
+22
+0.8% +$1.45K ﹤0.01% 2377
2019
Q2 		$167K Sell
2,600
-1,919
-42% -$182K ﹤0.01% 2430
2019
Q1 		$621K Sell
4,519
-645
-12% -$78.6K ﹤0.01% 2039
2018
Q4 		$467K Buy
5,164
+2
+0% +$280 ﹤0.01% 2102
2018
Q3 		$784K Buy
5,162
+7
+0.1% +$1.13K ﹤0.01% 1967
2018
Q2 		$887K Hold
5,155
– – ﹤0.01% 1893
2018
Q1 		$757K Buy
5,155
+2
+0% +$384 ﹤0.01% 1909
2017
Q4 		$1.04M Sell
5,153
-16,233
-76% -$3.34M ﹤0.01% 1798
2017
Q3 		$6.86M Sell
21,386
-1,835
-8% -$502K ﹤0.01% 1397
2017
Q2 		$5.25M Sell
23,221
-12,619
-35% -$2.59M ﹤0.01% 1409
2017
Q1 		$8.08M Sell
35,840
-1,744
-5% -$354K ﹤0.01% 1368
2016
Q4 		$7.44M Sell
37,584
-90
-0.2% -$19.6K ﹤0.01% 1364
2016
Q3 		$9.26M Sell
37,674
-19,705
-34% -$6.91M ﹤0.01% 1330
2016
Q2 		$33.3M Buy
57,379
+9,837
+21% +$5.77M 0.01% 922
2016
Q1 		$25.3M Sell
47,542
-541
-1% -$282K 0.01% 1006
2015
Q4 		$33.7M Buy
48,083
+132
+0.3% +$86.8K 0.01% 907
2015
Q3 		$27.8M Sell
47,951
-103
-0.2% -$84K 0.01% 973
2015
Q2 		$39M Buy
+48,054
New +$41.9M 0.01% 926

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's MCRB Position: Q4 2024 in Review

T. Rowe Price Associates sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 3,370 shares — an estimated $64K sold.

T. Rowe Price Associates first reported a position in MCRB in Q2 2015 and held it in 38 quarters. The position peaked at $46.1M in Q4 2020. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

  • T. Rowe Price Associates reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,370 Seres Therapeutics shares in Q4 2024, an estimated $64K.
  • T. Rowe Price Associates first reported a position in Seres Therapeutics in Q2 2015 and held it in 38 quarters.
  • T. Rowe Price Associates's Seres Therapeutics position peaked at $46.1M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.